Compounded Tirzepatide in New York, Prescribed Online

How tirzepatide gets prescribed in New York, online

Protocol MD serves patients in all 50 states, New York among them, and none of it needs a waiting room: you complete an assessment, a physician licensed in New York reads it, and a pharmacy ships to your New York address. In a state where a weekday appointment can cost you half a day, that is most of the appeal.

Three steps, in order. You consent to telehealth and complete the assessment covering your goals, your medical history and every medication and supplement you take. A physician licensed in New York reviews it, comes back for anything missing, then decides: prescribe compounded tirzepatide, point you toward a different route, or decline and explain why. If it is approved, a US-licensed 503A compounding pharmacy dispenses and ships it.

Your card is held at checkout and charged only after the physician approves. If the physician declines, the hold is released and you are not charged. Consider the source while you read this, too: Protocol MD sells compounded tirzepatide and makes money when a patient starts treatment, which is exactly why the clinical call sits with an independent physician who is paid to review your file whichever way it goes.

Does New York require an in-person visit for a tirzepatide prescription?

No. New York defines telehealth to include store-and-forward care in Public Health Law section 2999-cc and leaves the format of a first evaluation to the physician's professional standard of care. No New York statute or regulation forces a video call before a prescription for a medication that is not a controlled substance.

The rule people confuse this with is real, but it governs a different class of drug. 10 NYCRR 80.63(d), as amended effective May 21, 2025, says no controlled substance may be prescribed before an in-person medical evaluation by the prescribing practitioner, and subdivision (e)(4) carves out telemedicine and telehealth where it is consistent with state law and with the rules of the Drug Enforcement Administration. Tirzepatide is not a controlled substance, federally or in New York, so section 80.63 does not reach it. If you have been reading about New York and in-person evaluations, that is the regulation you found, and it is about controlled substances rather than GLP-1 medications.

So the format is open and the substance is not. The New York-licensed physician reading your assessment decides whether what you submitted is enough to prescribe from, or whether a live conversation has to happen first. An assessment that answers nothing does not become sufficient merely because New York permits asynchronous care.

Who prescribes it: a physician licensed in New York

Where you are sitting decides the license, not where the physician is, and New York is unusually strict about it. According to the State Education Department, practicing medicine in New York requires a New York license, and a license from another state does not qualify on its own. New York has also not joined the Interstate Medical Licensure Compact, so there is no compact shortcut an out-of-state physician can use to reach you faster.

That is checkable rather than something you have to take on trust. The State Education Department's Office of the Professions verification search returns license status for every physician it licenses. If a telehealth company will not tell you which New York-licensed physician signed your prescription, that is an answer in itself.

This page was reviewed by Dr. Richard Dentico, MD. Clinical decisions for New York patients are made by the independent New York-licensed physicians in Protocol MD's affiliated provider network, not by Protocol MD.

Who may ship compounded tirzepatide into New York

Under Education Law section 6808-b, a pharmacy outside New York that ships prescription drugs to patients in the state must be registered with the State Education Department, hold a license in good standing in its home state, and offer a toll-free line that reaches a pharmacist with access to your records. That last condition is worth knowing you have: New York entitles you to a pharmacist on the phone, not merely a support inbox.

Protocol MD prescriptions are filled by a US-licensed 503A compounding pharmacy; under New York law, a pharmacy shipping to you must hold the New York registration or license described here. Tirzepatide is an injectable, so what arrives is a sterile preparation compounded against your individual prescription. If you are comparing New York providers, ask the blunt version of the question: which pharmacy fills it, and is that pharmacy registered to ship into New York? A provider should be able to answer.

Who may be a candidate, and who should not take tirzepatide

Whether compounded tirzepatide fits you is the New York-licensed physician's judgment, built from your history, your current medications and what you are trying to change. It is a prescription medicine rather than a supplement, and being declined is a real result of the assessment rather than a formality it was built to wave through.

Some people should not take it at all. The brand-name tirzepatide label carries a boxed warning about thyroid C-cell tumors, so a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 (MEN 2) rules it out, and it is not used in pregnancy. Gastrointestinal effects are the common ones; our tirzepatide side effects guide covers what they look like and when to call a clinician.

How long you stay on it, and whether anything about the dose changes, are decisions your prescribing physician makes with you rather than a schedule we publish. Nothing on this page is a dose to follow. Protocol MD does not offer GLP-1 microdosing.

Bloodwork for New York patients

If bloodwork belongs in your plan, you order the panel yourself and the draw happens at Labcorp, which runs patient service centers across New York State; Protocol MD does not use any other lab network. Your results land in your patient portal, and you get an email, usually within 3-5 business days of your draw.

Which markers get run, and whether any of them are looked at again later, is your physician's clinical call rather than an interval Protocol MD publishes. No lab result is required before you start the assessment.

What compounded tirzepatide costs in New York

Protocol MD is cash-pay in New York. There is no membership fee, there is no insurer to bill, and compounded tirzepatide costs the same at every dose, so what you pay does not climb as the physician adjusts treatment. Current pricing lives on the product page rather than here, where it would go stale.

Comparing New York quotes is harder than it looks, because the quotes are not built the same way. Some include the physician review and the shipping; some add them afterwards; some are an introductory month that resets. Ask what a number covers before you put it next to another number.

Does New York Medicaid cover brand-name GLP-1 medications for weight loss?

Not for weight loss. New York Medicaid treats weight loss as a non-covered indication, so GLP-1s are excluded for it under the NYRx notice, which names the brand-name GLP-1 products. State employees sit in a different position: the brand-name tirzepatide product appears with prior authorization in the Empire Plan January 2026 formulary.

If you expected New York Medicaid to pay for a brand-name GLP-1 and found that it will not, that is a coverage decision rather than a judgment about the medicine. Commercial plans in New York vary far too much to generalize about, so read your own formulary instead of a neighbor's answer.

None of it changes what you pay here, because Protocol MD does not bill Medicaid or any insurer.

What compounded tirzepatide is, and what it isn't

Tirzepatide is a single molecule acting on two incretin receptors, GIP and GLP-1, given once weekly with the dose raised in steps under supervision. What Protocol MD ships is compounded by a US-licensed 503A pharmacy against an individual prescription, and it is an injection. There is no oral tirzepatide in the Protocol MD catalog, so if that is what you searched for, an injection is what this page describes.

Compounded medications are not FDA-approved and have not been evaluated by the FDA for safety or effectiveness. The SURMOUNT trials studied the brand-name product, so neither those approvals nor those results carry across to a compounded preparation, and compounded tirzepatide is not a generic of or a substitute for any brand-name product. The brand-name products are the FDA-approved option and remain a reasonable thing to raise with any physician; the FDA's own guidance is that compounded drugs should only be used in patients whose medical needs cannot be met by an FDA-approved drug. Weighing tirzepatide against the other GLP-1? Start with compounded semaglutide.